Corona Remedies IPO

Corona Remedies IPO

Listed

MainboardOpens 8 December 2025Closes 10 December 2025

Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto,…

Show more
Live GMPSubscriptionAllotment
Price band
₹1008 - ₹1062
Issue size
₹655.37 Cr
Lot size
14 shares
Type
Mainboard
GMP
₹342 (+32.2%)
Est. listing
₹1,404
Est. profit / app
₹4,788
Retail quota
35%

Key ratios

As per RHP / filings
Face value
₹10
EPS
30.21
P/E ratio
35.15
RoNW
24.65%
ROE
27.5%
Debt / Equity
0.1
Advertisement

Timeline

IPO Opens

8 Dec

IPO Closes

10 Dec

Allotment

11 Dec

Listing

15 Dec

IPO Timeline & Listing Details

EventDate
IPO Open Date8 December 2025
IPO Close Date10 December 2025
Allotment Date11 December 2025
Listing Date15 December 2025

Investment Categories

CategoryLotsAmount
Retail (Min)
1₹14,868
Retail (Max)Just less than ₹2,00,000
13₹1,93,284
SHNI (Min)Just above ₹2,00,000
14₹2,08,152
SHNI (Max)Below ₹10,00,000
67₹9,96,156
BHNIAbove ₹10,00,000
68₹10,11,024

IPO Reservation Details

CategoryReservation
QIB (Qualified Institutional Buyer)50%
NII (Non-Institutional Investor)15%
Retail35%
Total100.00%

IPO Objectives

  • The IPO is entirely an Offer for Sale (OFS). The company will not receive any proceeds. All funds raised (₹655.37 Cr) will go to the selling shareholders (promoters and marquee investors).

Strengths

  • The company has a Strong Growth Trajectory, being the second fastest-growing company among the top 30 IPM players by domestic sales (16.77% CAGR).
  • It shows High Profitability & Capital Efficiency, reporting exceptional ROCE of 41.32% and ROE of 27.50% (FY25), and a strong EBITDA margin of 20.55%.
  • The Chronic Therapy Focus (women’s health, cardio-diabeto) provides stable, recurring revenue similar to a subscription model.
  • The business maintains a Clean Balance Sheet with minimal financial leverage and a low Debt/Equity ratio of 0.10 (FY25).
  • It has a Pan-India Sales Network with 2,671 medical representatives, ensuring deep market penetration.

Weaknesses

  • The IPO is a Pure Offer for Sale (OFS), meaning the company will not receive any proceeds to fund future growth or balance sheet improvements directly.
  • The High Valuation with a P/E ratio of 35.15x (Post-IPO) is priced at a premium compared to many broad-spectrum peers.
  • Therapeutic Concentration (over 65% of revenue from three main areas) increases vulnerability to competition or regulatory changes in those specific categories.
  • The Regulatory Risk stems from branded generics in India being subject to government-imposed price caps (NLEM), which could impact margins.
  • Supplier Dependency is high, as the company relies entirely on third-party suppliers for raw materials, posing supply chain and cost risks.
Advertisement

Financial Performance

Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets (₹ Cr.)1,012.38929.86830.58595.02
Revenue (₹ Cr.)348.561,202.351,020.93891.1
PAT (₹ Cr.)46.2149.4390.584.93
Net Worth (₹ Cr.)607.02606.34480.41408.52

Peer Comparison

CompanyP/B RatioP/E RatioRONW (%)Net Worth (₹ Cr.)
Corona Remidies10.7135.1527.5%607.02
Abbott India Ltd.15.340.6637.62%4,233
Alkem Laboratories5.128.2217.69%12,434

Subscription Details

Daily Bids Status

CategoryDay 1Day 2Day 3
QIB0x1.76x293.8x
NII0.84x28.37x220.18x
S-HNI1.45x27.07x167.2x
B-HNI0.53x29.02x246.67x
RII0.96x6.9x30.39x
EMP1.48x4.37x15.56x
Total0.67x9.96x144.54x

Overall Subscription Statistics

CategoryShares OfferedShares BidBid Amount (₹ Cr)
QIB12,21,72935,89,39,44838,119.37
NII9,16,96020,18,97,06621,441.47
Small NII3,05,6535,11,03,7105,427.21
Big NII6,11,30715,07,93,35616,014.25
RII21,39,5736,50,16,3226,904.73
EMP58,0369,02,79095.88
Total43,36,29862,67,55,62666,561.45
Advertisement

Company Details

  • Corona Remedies Ltd.
  • CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat-380059
  • +91 79 4023 3000
  • complianceofficer@coronaremedies.com
  • https://www.coronaremedies.com/

Registrar Details

Frequently Asked Questions

What is the core therapeutic focus of Corona Remedies?
Corona Remedies focuses on high-margin branded formulations in chronic therapies, primarily women’s healthcare, cardio-diabeto, pain management, and urology.
When will the Corona Remedies IPO open and close for subscription?
The Corona Remedies IPO is currently open for subscription from December 8, 2025, and will close on December 10, 2025.
What is the IPO price band and listing date?
The price band is set at ₹1008.00 to ₹1062.00 per share, and the tentative listing date on the BSE and NSE is December 15, 2025.
Is the Corona Remedies IPO a Fresh Issue or Offer for Sale (OFS)?
The issue is entirely an Offer for Sale (OFS) of ₹655.37 Cr. This means the company will not receive any proceeds; all funds will go to the selling shareholders.
What are the key financial strengths and valuation metrics of Corona Remedies?
The company is valued at a Post-IPO P/E of 35.15x (based on H1 FY26 annualized EPS). Key strengths include an excellent ROCE of 41.32%, PAT margin of 12.49%, and a low Debt/Equity ratio of 0.10.
Does Corona Remedies offer a discount to employees?
Yes, eligible employees bidding in the reserved category are being offered a discount of ₹54 per share.

Corona Remedies IPO News & Updates

Follow the latest updates for Corona Remedies IPO, including grey market moves and allotment news.

Corona Remedies IPO IPO Pages

Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.

Corona Remedies IPO Details

Issue size, price, financials, and company info

Corona Remedies IPO GMP

Live grey market premium and listing estimate

Corona Remedies IPO Subscription

QIB, NII, Retail, SHNI and BHNI subscription

Corona Remedies IPO Allotment

Allotment date, chances, and check by PAN

Corona Remedies IPO Review

SWOT, strengths, risks, and IPO review

Corona Remedies IPO FAQ

Common questions on dates, GMP, and allotment

Corona Remedies IPO Registrar

Registrar website and how to check allotment

Corona Remedies IPO Timeline

Open, close, allotment, and listing dates

Corona Remedies IPO News

Updates, blogs, and latest IPO news

Sources

We match Corona Remedies IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.

  • SEBIRules for IPO allotment and disclosures in India
  • NSEExchange notices, bidding data, and listing updates
  • BSEExchange notices and IPO allotment check tools
  • RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
  • Bigshare Services Pvt.Ltd.Official site to check allotment status for this IPO

Also read our Editorial Policy, How GMP is calculated, How allotment chances work, and IPO fund allocation.

Reviewed by

Dinesh Agrawal · Lead IPO Analyst

15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.

Loading comments...